Abstract
IntroductionWe aimed to compare the prognostic value of a quantitative CT severity score with several laboratory parameters, particularly C-reactive protein, Procalcitonin, Neutrophil to lymphocyte ratio, D-dimer, ferritin, lactate dehydrogenase, lactate, troponin and B-type Natriuretic Peptide in predicting in-hospital mortality. MethodsThis was a retrospective chart review study of COVID-19 patients who presented to the Emergency Department of a tertiary care center between February and December 2020. All patients ≥18 years old who tested positive for the COVID-19 real-time reverse transcriptase polymerase chain reaction and underwent CT imaging at presentation were included. The primary outcome was the prognostic ability of CT severity score versus biomarkers in predicting in-hospital mortality. ResultsThe AUCs were: D-dimer (AUC: 0.67 95% CI = 0.57–0.77), CT severity score (0.66, 95% CI = 0.55–0.77), LDH (0.66, 95% CI = 0.55–0.77), Pro-BNP (0.65, 95% CI = 0.55–0.76), NLR (0.64, 95% CI = 0.53–0.75) and troponin (0.64, 95% CI = 0.52–0.75). In the stepwise logistic regression, age (OR = 1.07 95% CI = 1.05–1.09), obesity (OR = 2.02 95% CI = 1.25–3.26), neutrophil/lymphocyte ratio (OR = 1.02 95% CI = 1.01–1.04), CRP (OR = 1.01 95% CI = 1.004–1.01), lactate dehydrogenase (OR = 1.003 95% CI = 1.001–1.004) and CT severity score (OR = 1.17 95% CI = 1.12–1.23) were significantly associated with in-hospital mortality. ConclusionIn summary, CT severity score outperformed several biomarkers as a prognostic tool for covid related mortality. In COVID-19 patients requiring lung imaging, such as patients requiring ICU admission, patients with abnormal vital signs and those requiring mechanical ventilation, the results suggest obtaining and calculating the CT severity score to use it as a prognostic tool. If a CT was not performed, the results suggest using LDH, CRP or NLR if already done as prognostic tools in COVID-19 as these biomarkers were also found to be prognostic in COVID-19 patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.